Evidence map›Paper›PMID 25899847›Full record

ArticleAnnals of neurology2015

Ketone bodies mediate antiseizure effects through mitochondrial permeability transition.

Do Young Kim, Kristina A Simeone, Timothy A Simeone, Jignesh D Pandya, Julianne C Wilke, Younghee Ahn, James W Geddes, Patrick G Sullivan, Jong M Rho

Open access · greenAbstract read
In one paragraph

Article in Annals of neurology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 114 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
114citing papers in PubMed, 1 pooled it
11.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

114 citing papers in PubMed, 1 synthesis or guideline pooled it, 185 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

54 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Do Young KimBarrow Neurological Institute, St Joseph's Hospital and Medical Center, Phoenix, AZ.
Kristina A SimeoneDepartment of Pharmacology, Creighton University School of Medicine, Omaha, NE.
Timothy A SimeoneDepartment of Pharmacology, Creighton University School of Medicine, Omaha, NE.
Jignesh D PandyaSpinal Cord and Brain Injury Research Center, University of Kentucky, Lexington, KY.
Julianne C WilkeBarrow Neurological Institute, St Joseph's Hospital and Medical Center, Phoenix, AZ.
Younghee AhnDepartments of Pediatrics and Clinical Neurosciences, Alberta Children's Hospital Research Institute for Child and Maternal Health, University of Calgary Faculty of Medicine, Calgary, Alberta, Canada.
James W GeddesSpinal Cord and Brain Injury Research Center, University of Kentucky, Lexington, KY.
Patrick G SullivanSpinal Cord and Brain Injury Research Center, University of Kentucky, Lexington, KY.
Jong M RhoDepartments of Pediatrics and Clinical Neurosciences, Alberta Children's Hospital Research Institute for Child and Maternal Health, University of Calgary Faculty of Medicine, Calgary, Alberta, Canada.
University of Kentucky · USBarrow Neurological Institute · USCreighton University · USUniversity of Calgary · CA

Funding

UK Spinal Cord &Brain Injury Research Center Core GrantP30NS051220 · NINDS · UNIVERSITY OF KENTUCKY · PI HALL, EDWARD D. · 2005 to 2015
$6.4M
Metabolic Mechanisms of Functional Neuroprotection in Epileptic BrainR01NS070261 · NINDS · ST. JOSEPH'S HOSPITAL AND MEDICAL CENTER · PI KIM, DO YOUNG · 2010 to 2014
$1.6M
Cyclophilin D as a Therapeutic Target following Traumatic Brain InjuryR01NS062993 · NINDS · UNIVERSITY OF KENTUCKY · PI GEDDES, JAMES W., SULLIVAN, PATRICK G · 2009 to 2013
$1.6M
Mitochondrial Uncoupling as a Therapeutic Target in TBIR01NS048191 · NINDS · UNIVERSITY OF KENTUCKY · PI SULLIVAN, PATRICK G · 2004 to 2008
$1.5M
Adenosine, Hypocretin and Sleep Disorder Comorbidities Associated with EpilepsyR01NS072179 · NINDS · CREIGHTON UNIVERSITY · PI SIMEONE, KRISTINA A · 2012 to 2016
$1.5M
Canadian Institutes of Health ResearchNINDS NIH HHS P30 NS051220NINDS NIH HHS R01 NS048191NINDS NIH HHS R01 NS062993NINDS NIH HHS R01 NS070261NINDS NIH HHS R01 NS072179
6 · The paper itself

Abstract

objectiveKetone bodies (KB) are products of fatty acid oxidation and serve as essential fuels during fasting or treatment with the high-fat antiseizure ketogenic diet (KD). Despite growing evidence that KB exert broad neuroprotective effects, their role in seizure control has not been firmly demonstrated. The major goal of this study was to demonstrate the direct antiseizure effects of KB and to identify an underlying target mechanism.

methodsWe studied the effects of both the KD and KB in spontaneously epileptic Kcna1-null mice using a combination of behavioral, planar multielectrode, and standard cellular electrophysiological techniques. Thresholds for mitochondrial permeability transition (mPT) were determined in acutely isolated brain mitochondria.

resultsKB alone were sufficient to: (1) exert antiseizure effects in Kcna1-null mice, (2) restore intrinsic impairment of hippocampal long-term potentiation and spatial learning-memory defects in Kcna1-null mutants, and (3) raise the threshold for calcium-induced mPT in acutely prepared mitochondria from hippocampi of Kcna1-null animals. Targeted deletion of the cyclophilin D subunit of the mPT complex abrogated the effects of KB on mPT, and in vivo pharmacological inhibition and activation of mPT were found to mirror and reverse, respectively, the antiseizure effects of the KD in Kcna1-null mice.

interpretationThe present data reveal the first direct link between mPT and seizure control, and provide a potential mechanistic explanation for the KD. Given that mPT is increasingly being implicated in diverse neurological disorders, our results suggest that metabolism-based treatments and/or metabolic substrates might represent a worthy paradigm for therapeutic development.

Indexed as

Diet, KetogenicEpilepsy, Temporal Lobe3-Hydroxybutyric AcidAnimalsAnticonvulsantsBrainDisease Models, AnimalElectroencephalographyKetone BodiesKv1.1 Potassium ChannelMiceMice, KnockoutMitochondriaMitochondrial Membrane Transport ProteinsMitochondrial Permeability Transition PorePatch-Clamp Techniques3-Hydroxybutyric AcidAnticonvulsantsKcna1 protein, mouseKetone BodiesKv1.1 Potassium ChannelMitochondrial Membrane Transport ProteinsMitochondrial Permeability Transition Pore

Identifiers

PMID25899847
PMCPMC4480159
OpenAlexW1931245501

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.